Background: Therapeutic focused-ultrasound to the hippocampus has been reported to exert neuroprotective effects on dementia. In the present study, we examined whether the whole-brain LIPUS (lowintensity pulsed ultrasound) therapy is effective and safe in 2 mouse models of dementia (vascular dementia, VaD and Alzheimer's disease, AD), and if so, to elucidate the common underlying mechanism(s) involved. Methods: We used bilateral carotid artery stenosis (BCAS) model with micro-coils in male C57BL/6 mice as a VaD model and 5XFAD transgenic mice as an AD model. We applied the LIPUS therapy (1.875 MHz, 6.0 kHz, 32cycles) to the whole brain. Results: In both models, the LIPUS therapy markedly ameliorated cognitive impairments (Y-maze test and/or passive avoidance test) associated with improved cerebral blood flow (CBF). Mechanistically, the LIPUS therapy significantly increased CD31-positive endothelial cells and Olig2-positive oligodendrocyte precursor cells (OPCs) in the VaD model, while it reduced Iba-1-positive microglias and amyloid-b (Ab) plaque in the AD model. In both models, endothelium-related genes were significantly upregulated in RNA-sequencing, and expressions of endothelial nitric oxide synthase (eNOS) and neurotrophins were upregulated in Western blotting. Interestingly, the increases in glia cells and neurotrophin expressions showed significant correlations with eNOS expression. Importantly, these beneficial effects of LIPUS were absent in eNOS-knockout mice. Conclusions: These results indicate that the whole-brain LIPUS is an effective and non-invasive therapy for dementia by activating specific cells corresponding to each pathology, for which eNOS activation plays an important role as a common mechanism.
Novel, effective strategies for treating dementia are urgently needed, particularly given alarming increases in the global prevalence of dementia. According to the current estimates, nearly 47 million patients worldwide had dementia in 2015, and this number is estimated to exceed 131 million by 2050 [1] . However, no curative treatment is yet available for vascular dementia (VaD) or Alzheimer's disease (AD) [2, 3] , both of which comprise the most common causes of dementia. VaD and AD share risk factors, such as hypertension, hypercholesterolemia, and diabetes mellitus [2, 3] . Long-term exposure to these risk factors results in common outcome, i.e., impairment of vascular endothelial functions [4] . Thus, the endothelium has been recognized as an important and common therapeutic target for prevention and treatment of dementia [4] .
Among several reports on therapeutic applications of ultrasound technology, low-intensity pulsed ultrasound (LIPUS) has emerged as a non-invasive therapy for several diseases. We have previously demonstrated that vascular endothelial cells substantially contribute to the therapeutic effect of LIPUS, inducing therapeutic angiogenesis in myocardial ischemia [5, 6] . Meanwhile, LIPUS has also been reported to increase the production of brain-derived neurotrophic factor (BDNF) in astrocytes [7] and nerve growth factor (NGF) in PC12 cells [8] , and to promote nerve regeneration [9] . Also, focused LIPUS to the hippocampus could ameliorate dementia (VaD and AD) in mice via increasing endogenous neurotrophins and vascular endothelial growth factor (VEGF) [10, 11] . However, it is still unknown what kind of cell type contributes to the LIPUS-induced cognitive improvement, and whether there is a common factor in the two disorders. Moreover, from clinical point of view, we hypothesized that whole-brain LIPUS, rather than focused ultrasound, is effective and feasible since VaD is characterized by the widespread white matter lesions (WML) and AD by the widespread deposition of amyloid-b (Ab) in the brain [2, 3] . Thus, in the present study, we aimed to examine the effectiveness and safety of whole-brain LIPUS therapy that has never been used before. We first examined whether the whole-brain LIPUS is effective in different mouse models of dementia (VaD and AD), and if so, to elucidate the common mechanism underlying the beneficial effects of LIPUS.
Methods
See Supplementary Methods.
Results

LIPUS therapy improves cognitive dysfunctions in the VaD model
In the VaD model, the LIPUS therapy ( Fig. 1A and B, Supplementary Figs. 1A and B) had no effects on body weight or systolic blood pressure ( Supplementary Fig. 1C ). LIPUS-treated mice showed no signs of cramps, paralysis, cerebral hemorrhage, hypothermia, hyperthermia, or increased mortality compared with control mice, which underwent the same procedure without LIPUS treatment (data not shown). In the Y-maze test, the number of entries was comparable between the LIPUS and control groups, suggesting that LIPUS causes no hyperactivity (Fig. 1C) . Next, the LIPUS-treated BCAS group had significantly improved performance for cognitive functions, including spontaneous alternation task in the Y-maze and retention in the passive avoidance test (Fig. 1C ). In the novel object recognition test, the LIPUS-treated BCAS group tended to have improved cognitive function compared with the control group (Fig. 1C) . Similar results were also obtained at 56 and 84 days after the LIPUS therapy ( Supplementary Fig. 1D ), and there were no side effects of LIPUS for 3 months (data not shown). The LIPUS therapy significantly improved cerebral blood flow (CBF) in the BCAS group for up to 28 days after the therapy, whereas it had no effect in the control groups (Fig. 1D) . Taken together, these results suggest that the cognitive improvement by the LIPUS therapy is associated with increased CBF and can last for at least 3 months.
LIPUS therapy improves WML in the VaD model
Next, we examined brain histology to determine the mechanism of the beneficial effects of the LIPUS therapy in the VaD model. We focused on the constituent cells of neurovascular unit possibly contributing to multifaceted actions of LIPUS. The results showed that the number of cells in the corpus callosum that were positive for GST-p, a marker of mature oligodendrocytes, was significantly higher in the LIPUS-treated group compared with the control group ( Fig. 2A) . In addition, Klüver-Barrera staining showed that the LIPUS therapy reduced the severity of WML following BCAS ( Fig. 2A) . Although there was no difference in CD31-positive cells in the corpus callosum (for assessment of capillary density), significantly more CD31-positive cells were present in the hippocampus of LIPUS-treated group compared with control group (Fig. 2A) . Compared with control group, LIPUS-treated group showed no difference in the number of cells positive for GFAP (glial fibrillary acidic protein; for astrocytes) or Iba-1 (ionized calcium-binding adapter molecule-1; for microglias) ( Supplementary Fig. 2 ). Moreover, doublecortin (DCX) staining of the hippocampus showed significantly more newly formed neurons in the dentate gyrus of LIPUS-treated group compared with control group (Fig. 2B, Supplementary Fig. 3 ). These results suggest that the LIPUS-induced angiogenesis ameliorates cognitive dysfunctions through neurogenesis and reduction of WML. Since we found no significant difference between the LIPUS-treated sham group and the control group, we focused on the BCAS group in the subsequent biochemical analyses. To examine the effects of the LIPUS therapy at the molecular level, we performed RNA-sequencing (RNA-seq) using total brain samples. The results showed that 3 days after BCAS, the expressions of~2000 genes differed significantly between the LIPUS-treated and control groups; specifically, 981 and 1239 genes were significantly upregulated and downregulated, respectively (Fig. 3A) . Gene ontology (GO) term analysis showed that the genes differentially regulated by the LIPUS therapy were enriched for genes that play a role in angiogenesis and proliferation (Fig. 3B ). Regarding the cell type responding to the LIPUS therapy, the highest number of LIPUSenhanced genes was annotated to astrocytes, followed by genes annotated to endothelial cells and oligodendrocytes (Fig. 3C) . Most of the genes listed as oligodendrocyte-related genes were annotated as playing a role in cell differentiation and development; however, since mature oligodendrocytes do not proliferate, these oligodendrocyte-related genes were likely to be oligodendrocyte precursor cells (OPCs). A heat map of upregulated and downregulated genes confirmed that the differentially expressed genes in response to LIPUS were related to astrocytes, OPCs, myelination, and angiogenesis (Fig. 3D) .
Abbreviations
To confirm our RNA-seq data, we performed RT-qPCR analyses for the following genes; GFAP (for astrocytes), Olig2 (for OPCs), eNOS (for angiogenesis and vasodilatation), and FGF-2 (fibroblast growth factor-2) and CXCR4 (CXC chemokine receptor 4) (for angiogenesis [12, 13] and OPC differentiation [14, 15] ). mRNA levels of all 5 genes were higher in the LIPUS group compared with the control group (Fig. 3E) .
In contrast, regarding the trend for improved histological and CBF state in the sham-operation group in response to LIPUS, we assumed the following hypothesis; since the sham-operation/LIPUS group underwent the same procedure with BCAS except the placement of micro-coils, those mice were under temporary ischemic burden. In fact, CBF in the sham-operated groups decreased to~90% compared with baseline CBF at 2 h to 7 days after operation. We do not consider that this mild decrease in CBF led to cerebral dysfunction including cognitive function. We rather hypothesize that LIPUS treatment has a potential to upregulate angiogenesis-related genes. To confirm this hypothesis, we performed RNA-seq analysis with sham group animals and found that LIPUS upregulated angiogenesis-related genes including eNOS ( Supplementary Fig. 4 ).
LIPUS increases the protein levels related to angiogenesis, OPCgenesis, and neurotrophins in the VaD model
Next, we examined the effect of the LIPUS therapy at the protein level. The results of multiplex analysis using Bio-Plex showed that LIPUS increased proteins in the MAPK (mitogen-activated protein kinase) pathway, including CREB (cAMP response element-binding protein), ERK1/2, MEK, p38 MAPK, and proteins downstream of the PI3K/Akt pathway, including p70 S6 kinase, whereas GSK-3ab was slightly but significantly decreased ( Supplementary Fig. 5A ). To confirm this finding, we measured the extent of phosphorylation of ERK1/2 and Akt, which are main mediators of the MAPK and PI3K-Akt pathways for angiogenesis and cell proliferation, respectively. We found that p-ERK1/2 was significantly increased in the LIPUStreated group on day 3, but not on day 7 ( Supplementary Fig. 5B ). In contrast, p-Akt did not differ between the LIPUS-treated and control groups at either time point ( Supplementary Fig. 5B ).
We thus measured the protein levels of GFAP, Olig2, eNOS, CXCR4, and FGF2 as mRNA expressions of those factors were increased by LIPUS, and nerve growth factor (NGF), pro-BDNF, and VEGF (vascular endothelial growth factor) as those were reported to be increased by LIPUS [7, 8] . As shown in Fig. 3F and Supplementary Fig. 5D , the protein levels of GFAP, p-eNOS, t-eNOS, FGF2, NGF, and pro-BDNF were significantly higher in the LIPUS group on day 3, whereas those of Olig2, CXCR4, and VEGF were unchanged at this time point. In contrast, t-eNOS, CXCR4, FGF2, VEGF, and NGF, but not GFAP, Olig2, p-eNOS or pro-BDNF, were significantly increased in the LIPUS group on day 7 ( Supplementary  Figs. 5C and 5D ). Interestingly, we found a positive correlation between eNOS expression and NGF, pro-BDNF, and VEGF (Fig. 3G) , indicating that the expression of neurotrophins is correlated with eNOS expression. Besides, LIPUS had no significant effect on neuronal NO synthase (nNOS) or inducible NO synthase (iNOS) at either time point (Supplementary Fig. 6A ). Thus, the upregulation of endogenous growth factors in the LIPUS-treated group may contribute to improved cognitive functions, for which eNOS plays an important role.
LIPUS enhances OPC proliferation in the VaD model
Mechanistically, we examined histological changes in the corpus callosum and hippocampus on day 3 after BCAS surgery. In the corpus callosum, the LIPUS therapy significantly increased the number of Olig2-positive cells in the BCAS group, but had no significant effect on GFAP-positive or Ki67-positive cells (Fig. 4A) . In contrast, in the hippocampus, LIPUS significantly increased the number of Ki67-positive cells in the BCAS group, but had no significant effect on GFAP-positive or Olig2-positive cells (Fig. 4A) . We also examined which cell types are involved in LIPUS-induced proliferation by co-immunostaining for Ki67 and Olig2, and found that the LIPUS therapy increases OPC proliferation (Fig. 4B ). In contrast, by staining both eNOS and CD31, we found that eNOS was expressed specifically in the vascular endothelium of the corpus callosum following the LIPUS therapy ( Supplementary Fig. 6B ). Furthermore, consistent with our Western blot analysis, immunostaining showed that eNOS expression was increased following the LIPUS therapy in the BCAS group ( Supplementary Fig. 6C ). We also found a positive correlation between eNOS and Olig2 and between eNOS and GFAP (Fig. 4C) . Taken together, these results suggest that the whole-brain LIPUS therapy in mice with BCAS activated OPCs and astrocytes associated with eNOS upregulation.
Essential role of eNOS in the beneficial effects of the LIPUS therapy in the VaD model
We next examined the role of eNOS in the LIPUS-induced improvement in cognitive function using eNOS-knockout (eNOS e/ e ) mice. The LIPUS therapy had no significant effect on BCASinduced changes in CBF (Fig. 5A) . Importantly, in eNOS e/e mice, LIPUS had no beneficial effects on BCAS-induced behavior outcome (Fig. 5B) , the number of GST-p-positive cells, the extent of WML, or the number of CD31-positive cells (Fig. 5C) . Moreover, the expression levels of VEGF and neurotrophins, both of which were significantly increased in LIPUS-treated wild-type mice with BCAS, were unaffected by the LIPUS therapy in eNOS e/e mice (Fig. 5D ). Thus, we conclude that eNOS is crucial for mediating the beneficial effects of the LIPUS therapy in the VaD model.
LIPUS therapy ameliorates cognitive dysfunctions in the AD model
Next, we examined the effect of another common form of dementia, Alzheimer's disease (AD), using 5XFAD mice (Fig. 6A) , an established mouse model of AD pathology [16] . We first confirmed that whole-brain LIPUS had no effects on body weight or systolic Fig. 7A ). Moreover, the LIPUS therapy did not cause cramps, paralysis, cerebral hemorrhage, hypothermia, hyperthermia, or death (data not shown) or hyperactivity (Fig. 6B) . Importantly, the LIPUS therapy significantly improved cognitive functions in 5XFAD mice in the spontaneous alternation task (Fig. 6B ). The LIPUS therapy had no significant effect in the passive avoidance test (Supplementary Fig. 7B ). Moreover, consistent with previous finding [17] , we found an agingdependent decrease in CBF in 5XFAD (Fig. 6C) . LIPUS had no effect on CBF in wild-type mice for 84 days after the treatment (Fig. 6C) . Interestingly, however, this decline in CBF in 5XFAD mice was ameliorated by the LIPUS therapy, resulting in significantly higher CBF in the LIPUS-treated group at 84 days after the treatment (Fig. 6C) .
Next, we performed RNA-seq analysis using whole-brain samples to compare the global gene expression patterns between LIPUS-treated and control 5XFAD mice on day 86. We found that nearly 2500 genes were differentially expressed in the LIPUS and the control groups, including 1354 upregulated and 1126 downregulated genes (Fig. 6D) . GO term analysis showed that the genes regulated by the LIPUS therapy in the 5XFAD mice encoded key regulators of immune function and angiogenesis (Fig. 6E) , similar to the genes identified in the VaD model. We next calculated the number of genes annotated to each type of cells as a percentage of the total number of genes, demonstrating that the majority of genes were annotated to microglia. Interestingly, endothelium-related genes were the second most frequently enhanced genes in this model as well as in the BCAS model (Fig. 6F) . The heat map expression confirmed that the LIPUS therapy significantly upregulated and/or downregulated genes related to amyloid, microglia, inflammation, and angiogenesis (Fig. 6G) . These results suggest that the LIPUS therapy suppressed chronic inflammatory response of microglias, and that endothelium-related genes were also enhanced in this model.
LIPUS therapy reduces microgliosis along with eNOS upregulation in the AD model
Based on the results from RNA-seq, we examined microgliosis and angiogenesis in those mice (Fig. 7A) . Histological analysis showed a significant reduction in microgliosis in the cortex of 5XFAD mice following the LIPUS therapy, reflecting a decrease in Iba-1-positive cells (Fig. 7A) . The number of CD31-positive cells tended to increase in the hippocampus of LIPUS-treated 5XFAD mice compared with the control group (Fig. 7A ). Since we found no significant difference between the LIPUS-treated and the control groups, we focused on the 5XFAD group in the subsequent biochemical analyses.
Next, we examined whether the LIPUS therapy affects eNOS expression in the 5XFAD mice since the significance of eNOS as a therapeutic target in AD has been recently reported [4] . Western blot analysis showed that the LIPUS therapy significantly increased t-eNOS protein levels in 5XFAD mice (Fig. 7B) , and this increase was correlated with a reduction in Iba-1-positive cells (Fig. 7C) . Furthermore, the expression of APP (amyloid precursor protein) and BACE-1 (b-site amyloid precursor protein cleaving enzyme-1), both of which are known to be suppressed by eNOS [18] , were significantly decreased by the LIPUS therapy ( Supplementary  Fig. 7C ). Hsp 90 (heat shock protein 90), an activator of eNOS [19] , was significantly increased by the LIPUS therapy ( Supplementary Fig. 7C ). In contrast, the protein levels of both NGF and pro-BDNF were significantly increased in LIPUS-treated mice compared with control mice, whereas VEGF levels were unchanged ( Supplementary Fig. 7D ). Importantly, we found a positive correlation between eNOS and pro-BDNF as well as in the VaD model (Fig. 7D) . Taken together, these results indicate that the wholebrain LIPUS therapy in the AD mice had potential to suppress neuroinflammation through suppression of microglia and amyloidb (Ab) accumulation associated with eNOS upregulation.
LIPUS therapy reduces Ab plaque in the AD model
Mechanistically, we performed histological and biochemical analyses to examine the effect of the LIPUS therapy on accumulation of Ab in the brain of 5XFAD mice. Interestingly, we found that LIPUS significantly decreased the Ab-42 plaque throughout the brain in 5XFAD mice (Fig. 8A) . Enzyme-linked immunosorbent assay (ELISA) showed that the amount of Ab-42 in the tritonsoluble fraction (which contains primarily oligomeric Ab [20] ) was decreased in the LIPUS-treated group (Fig. 8B) . In contrast, LIPUS had no effect on Ab-42 levels in the TBS-soluble fraction, which contains primarily monomeric Ab (Fig. 8B) [20] . Importantly, recruitment of microglia cells to Ab deposits were enhanced in LIPUS-treated mice compared with control mice (Fig. 8C) . These results suggest that the LIPUS therapy enhances the phagocytosis of Ab plaque.
Discussion
In the present study, we report the first experimental evidence that the whole-brain LIPUS therapy markedly improves cognitive dysfunctions without serious side effects in the 2 major mouse models of dementia (VaD and AD) by enhancing the specific cells corresponding to each pathology, and that eNOS plays important roles in mediating the beneficial effects of LIPUS (see Fig. 9 ). Since large molecules cannot cross the blood-brain barrier [21, 22] , the strategy to increase the local expression of endogenous neurotrophins is important for dementia. Furthermore, the present study provides 3 important advances in this field. First, our study shows that the whole-brain LIPUS therapy is effective and safe when applied in vivo. Second, we identified the main processes by which LIPUS improves cognitive dysfunctions, namely increased OPC production in the VaD model and reduced microgliosis in the AD model. Third, we were able to demonstrate that eNOS activation plays crucial and common roles in the beneficial effects of LIPUS therapy in both models of dementia.
LIPUS ameliorates cognitive dysfunctions by promoting OPC-, angiogenesis in the VaD model
The VaD model with BCAS is characterized by WML due to chronic cerebral ischemia, similar to patients with the disorder [23] . OPC proliferation is enhanced in WML in patients with multiple cerebral infarctions, suggesting that white matter has the capacity to regenerate via OPC proliferation following ischemic injury [24] . In the present study, the LIPUS therapy significantly increased the number of both OPCs and oligodendrocytes, suggesting the maturation and differentiation of oligodendrocytes from OPCs, ultimately leading to reduced WML. Moreover, OPCs themselves can contribute to angiogenesis following white matter injury [25] . Thus, LIPUS-induced OPC proliferation and angiogenesis may be a novel strategy that can improve cognitive dysfunction for VaD patients.
LIPUS ameliorates cognitive dysfunctions by reducing Ab and microgliosis in the AD model
The primary phenotype in 5XFAD mice includes the progressive accumulation of Ab and neuroinflammation, thereby mimicking the main pathological features of AD patients [16] . In the present study, the expression of APP and BACE-1 were significantly decreased by the LIPUS therapy, and Ab was significantly reduced in triton-soluble fraction and histological assessment. Regarding the mechanism of unchanged TBS soluble Ab levels, Ab is known to dissolve in a monomer form at concentrations lower than 3 mM, whereas it aggregates at concentrations higher than 3 mM [29] . In the present study, although the total amount of Ab was actually decreased by LIPUS treatment, more amount of Ab was produced than the amount that could dissolve in extracellular fluid. Thus, we consider that the amount of Ab in the extracellular fluid continued to be saturated, resulting in no difference in the TBS soluble fraction. On the other hand, it is generally accepted that microgliamediated neuroinflammatory responses can promote neurodegeneration in AD [26] . Thus, a strategy to suppress this microglial response could be a therapeutic approach for AD [26, 27] . However, since microglia acts in both protective and toxic manners, its function in AD is still controversial. In the present study, the ratio of recruited microglia to phagocytosis for amyloid plaque was significantly higher in the LIPUS-treated group (Fig. 7B) . Although the total number of Iba-1-positive microglia decreased by LIPUS, phagocytosis was rather enhanced in the LIPUS-treated group. Besides, Hsp 90, which is known to inhibit aggregation of Ab [28] , was enhanced by LIPUS in the present study, a consistent finding of the previous study [29] . Hsp 90 is promptly recruited by endothelial stimulation of shear stress induced by ultrasonic waves, and enhances eNOS activation [30] . Thus, we consider that LIPUS-induced reduction in Ab triton fraction and plaque load can be explained, at least in part, by the following mechanisms; (i) reduction in Ab production, (ii) the changes in characteristics of microglia, and (iii) refolding of Ab by Hsp 90. Multiple factors may be involved in the mechanisms of LIPUS-induced reduction in Ab triton fraction and plaque load. Further studies are needed to clarify the mechanisms of Ab plaque reduction by the LIPUS therapy.
4.3. Important roles of eNOS as a common mechanism in the two mouse models of dementia Our RNA-seq analyses with 2 different models of dementia revealed that the LIPUS therapy significantly upregulated genes related to vascular endothelial cells. In the VaD model, LIPUS improved CBF promptly after the LIPUS therapy, suggesting that the acute effect of LIPUS on CBF is likely to be mediated by a vasodilating factor rather than angiogenesis. eNOS produces relatively low concentrations of NO, which are essential for maintaining endothelial function and integrity [31, 32] . NO exerts a variety of physiological effects, including regulation of vascular tone and angiogenesis [32, 33] . Thus, eNOS activation is an effective therapeutic strategy for a variety of cardiovascular diseases [31, 32] . Moreover, in the hippocampus, eNOS plays a crucial role in longterm potentiation [34] . In endothelial cells, eNOS localizes in the caveolae, and its activity is controlled by binding with caveolin [30] . Cyclic strain induced by ultrasonic pulse activates mechanotransduction via mechanosensors [35] , such as caveolin, leading to eNOS activation [30] . Indeed, in the present study, eNOS was upregulated by LIPUS at both mRNA and protein levels. We also found a significant correlation between eNOS and activated glial cells/molecules in both models; eNOS and Olig2 expression/neurotrophins in the BCAS model and eNOS and Iba-1-positive cells/ neurotrophin in the AD model. eNOS e/e mice have activated microglial cells and spontaneously develop cognitive impairment [18] . Moreover, the factors contributing to Ab reduction, such as microglias, APP, BACE-1, and Hsp 90, are known to be linked with of endothelial cells may have significant effects on astrocytes, resulting in improvement of cognitive functions in the present study. The enhancement of GFAP expression also supports the involvement of astrocytes in the LIPUS-induced beneficial effects on cognitive functions.
Interpretation of the behavioral improvements
We consider that the behavioral improvements observed in the present study reflect improved cognition. In the present study, Y maze and novel object recognition test were analyzed independently for motor functions because they were corrected by calculating as ratio. In contrast, in passive avoidance test, the improvement of motor performance shortens the latency. In general, BCAS mice show motor dysfunction 3 month after operation [36] , while 5XFAD after 9 months of age [37] . In the present study, we performed behavioral tests at 1 month after operation in BCAS mice, and at 6e7 months in 5XFAD mice. In the Y maze test, we found no difference in the number of entries between LIPUS and control groups in both models.
Study limitations
Several limitations should be mentioned for the present study. First, in the present study, we were unable to examine the contribution of eNOS in 5XFAD mice because this model was technically difficult to generate. Second, the use of 5XFAD mice has some limitations. With this model, we were obviously unable to evaluate tau protein. Furthermore, 5XFAD mouse is a model of forced amyloidosis but not an actual human AD model. Third, we did not use endothelium-specific eNOS À/-mice. However, eNOS is mainly localized in endothelial cells, including the brain, which was also confirmed in the present study. Finally, we did not directly compare the effectiveness between our whole-brain LIPUS therapy and the focused LIPUS therapy to the hippocampus by others [10, 11] .
Conclusions
We were able to demonstrate that the whole-brain LIPUS is an effective and safe therapy for ameliorating cognitive dysfunction induced by either ischemia or overexpression of amyloid-related genes in mice, for which eNOS plays crucial roles to improve cerebral circulatory dysfunction. These findings suggest that wholebrain LIPUS therapy may be beneficial in vascular dementia and AD in humans.
